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Abstract
Background: Benign esophageal ruptures and anastomotic leaks are life-threatening conditions that are often
treated surgically. Recently, placement of partially and fully covered metal or plastic stents has emerged as a
minimally invasive treatment option. We aimed to determine the clinical effectiveness of covered stent placement
for the treatment of esophageal ruptures and anastomotic leaks with special emphasis on different stent designs.
Methods: Consecutive patients who underwent placement of a fully covered self-expandable metal stent (FSEMS),
a partially covered SEMS (PSEMS) or a self-expanding plastic stent (SEPS) for a benign esophageal rupture or
anastomotic leak after upper gastrointestinal surgery in the period 2007-2010 were included. Data on patient
demographics, type of lesion, stent placement and removal, clinical success and complications were collected
Results: A total of 52 patients received 83 esophageal stents (61 PSEMS, 15 FSEMS, 7 SEPS) for an anastomotic leak
(n = 32), iatrogenic rupture (n = 13), Boerhaave’s syndrome (n = 4) or other cause (n = 3). Endoscopic stent removal
was successful in all but eight patients treated with a PSEMS due to tissue ingrowth. Clinical success was achieved in
34 (76%, intention-to-treat: 65%) patients (PSEMS: 73%, FSEMS: 83%, SEPS: 83%) after a median of 1 (range 1-5) stent
and a median stenting time of 39 (range 7-120) days. In total, 33 complications in 24 (46%) patients occurred (tissue
in- or overgrowth (n = 8), stent migration (n = 10), ruptured stent cover (all Ultraflex; n = 6), food obstruction (n = 3),
severe pain (n = 2), esophageal rupture (n = 2), hemorrhage (n = 2)). One (2%) patient died of a stent-related cause.
Conclusions: Covered stents placed for a period of 5-6 weeks may well be an alternative to surgery for treating
benign esophageal ruptures or anastomotic leaks. As efficacy between PSEMS, FSEMS and SEPS is not different, stent
choice should depend on expected risks of stent migration (SEPS and FSEMS) and tissue in- or overgrowth (PSEMS).
Background
Esophageal ruptures and anastomotic leaks are life-threa-
tening injuries with a high mortality rate [1-7]. Most rup-
tures occur after (endoscopic) instrumentation or surgery,
i.e. leaking anastomosis, but may also occur spontaneously
after vomiting (Boerhaave’s syndrome) [8]. Surgical repair
including surgical closure or cervical exclusion or esopha-
gectomy has long been considered to be ‘gold standard’
[4,8-12]. Although surgery improves survival, it has been
reported to be associated with a high mortality rate (30%),
especially after a delayed diagnosis [2].
Endoscopic stent placement is a well accepted and effec-
tive treatment for malignant dysphagia [13]. Recently, tem-
porary endoscopic stent placement, either with fully
(FSEMS) or partially (PSEMS) covered self-expanding
metal stents or a self-expanding plastic stent (SEPS), has
emerged as a minimally invasive treatment option for
benign esophageal ruptures and leaks. A favorable out-
come with low morbidity and mortality has been reported
[14-19]. Stents are able to effectively seal leaks and offer
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takes place when adequate drainage of fluid collections
from the mediastinum or pleural cavity is concurrently
performed. The main drawbacks of stent placement are
tissue in- or overgrowth and stent migration necessitating
reinterventions. Particularly, reactive nonmalignant tissue
in- or overgrowth and embedding of the stent in the eso-
phageal wall may be a problem, especially when partially
covered stents are left in place for a longer duration. Endo-
scopic stent removal in case of severe stent embedding
may cause esophageal perforation [20]. On the other hand,
migration rates are higher when fully covered stents, either
SEMS or SEPS, are used [21-23].
Experience with temporary stenting for nonmalignant
esophageal ruptures or anastomotic leaks is limited and
studies comparing surgery with stent placement have
not been performed. In addition, studies comparing
FSEMS, PSEMS and SEPS for the treatment of benign
esophageal ruptures and leaks are not available.
In this study, we evaluated safety and clinical effective-
ness of treating benign esophageal ruptures and anasto-
motic leaks with covered stents, with special emphasis
on different stent designs.
Methods
Patients
All patients who had received a self-expandable metal or
plastic stent for sealing a benign esophageal rupture or
anastomotic leak after esophageal or gastric surgery in
the period January 1, 2007-January 1, 2010 were enrolled
in this study. Data on patient demographics, type and
cause of lesion, stent type, placement and removal details,
clinical success (sealing rate), complications, reinterven-
tions and mortality were retrospectively collected.
Patients with malignant fistulas or ruptures, or for whom
no follow-up information was available were excluded
(10%).
Esophageal stents
All patients received a covered esophageal stent, a
PSEMS, FSEMS or SEPS (see below).
The PSEMS used in our study were the:
- Ultraflex stent (Boston Scientific, Natick, MA),
length 120 mm, cover 90 mm, diameter 28/23 mm, or
length 150 mm, cover 120 mm, diameter 23/18 mm;
- WallFlex Esophageal Stent (Boston Scientific), length
120 mm, cover 90 mm, diameter 28/23 mm.
The FSEMS used were the:
- SX-ELLA Stent Esophageal HV (ELLA-CS, Hradec
Králové, Czech Republic), length 85 mm, diameter 25/20/
25 mm or length 110 mm, diameter 25/20/25 mm;
- ALLIMAX-E Esophageal stent (Alveolus, Charlotte,
NC), length 120 mm, diameter 22 mm;
- Choo stent (M.I. Tech, Seoul, South Korea), length
60 mm, diameter 18 mm.
The SEPS used was the Polyflex Esophageal Stent
(Boston Scientific), length 90 mm, diameter 25/21 mm.
Endoscopic stent placement was performed under
fluoroscopic control. Endoscopic stent removal was per-
formed with a rat-tooth forceps grasping the proximal end
of the stent; only some of the Ultraflex stents were grasped
distally, resulting in removal of an inverted stent. When
endoscopic stent removal was expected to be complicated
due to tissue ingrowth (PSEMS) and/or overgrowth (all
stent types), a FSEMS of the same size was placed inside
the stent. This stent at least overlapped the previously
placed stent and induced pressure necrosis of the tissue
in- or overgrowth. This resulted in uncomplicated removal
of both stents after 10-14 days (stent-in-stent method)
[24]. After stent removal, an endoscopy and/or a water-
soluble contrast esophagogram was performed to confirm
sealing. All endoscopic procedures were performed under
conscious sedation (midazolam or propofol) or general
anesthesia according to the patient’s condition.
Endpoints
Primary endpoint of the study was clinical success defined
as sealing of a rupture or leak as confirmed by endoscopy
and an additional esophagogram in case of doubt. Second-
ary outcomes included technical success of stent placement
and removal, complication rates and survival. For technical
outcome we registered details on stent deployment and
placement at the required location. Removal was consid-
ered to be successful when the stent could be removed as a
whole and without complications in one session. Compli-
cations included stent- and procedure-related adverse
events.
Statistical analysis
The following variables were included in the analyses: a)
clinical characteristics: age, gender, lesion length, location
and etiology, and prior treatment, b) outcome and survi-
val: technical success, clinical success, survival and cause
of death, and c) complications. Results were expressed as
mean ± SD and medians with range, as appropriate. Chi-
Square test and Kruskal Wallis test were used as appro-
priate. All analyses were performed on an intention-to-
treat (ITT) basis. A p-value <0.05 was considered statisti-
cally significant. Statistical analyses were conducted using
SPSS version 15 (SPSS Inc, Chicago, Ill. USA).
Results
Clinical characteristics
In total, 52 patients treated with 83 covered self-expand-
able stents were included in three different hospitals
(University Medical Center Utrecht n = 25, Medical
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Ziekenhuis Nieuwegein n = 12). Clinical characteristics
of the patients are shown in Table 1. More than half of
the patients had an anastomotic leak after gastrectomy
with esophagojejunostomy (n = 15), (transhiatal) eso-
phagectomy with gastric tube formation (n = 9), gastric
bypass (n = 6) or resection of an esophageal diverticu-
lum (n = 1). Iatrogenic esophageal ruptures occurred
during the following procedures: pneumatic dilation
(n = 6), tracheal intubation (n = 3), esophageal stenting
for benign strictures (n = 2), Nissen fundoplication (n =
1), a Belsey Mark IV procedure (n = 1) and mediano-
scopic biopsy taking (n = 1). Other causes included
Boerhaave syndrome (n = 4), a rupture following radia-
tion therapy (n = 1), spontaneous rupture above an
impacted food bolus (n = 1) and disruption of a med-
iastinal abscess (n = 1). Most patients (n = 41 (79%))
received antibiotic treatment. In 24 (46%) patients, con-
current drainage of the pleural cavity (n = 12), mediasti-
num (n = 4) or both (n = 8) was performed either
surgically (n = 18 (75%)) or radiologically (n = 6 (25%)).
In total, 83 stents (median 1, range 1-10) were placed,
of which 61 (74%) were PSEMS, 15 (18%) FSEMS and 7
(8%) SEPS. The median number of days of stent place-
ment was 39 days (range 1-742). In one patient with an
anastomatic leak after (transhiatal) esophagectomy, a
total of 10 stents was placed resulting in a total stenting
time of 742 days.
Median follow up was 470 days (range 25-1200 days).
Stent placement and removal
Eighty-two of 83 (99%) stents were successfully placed
(Table 2). In one patient, a PSEMS was placed too proxi-
mally and could not be repositioned. Therefore, a second
Table 1 Clinical characteristics of 52 patients treated with an esophageal stent for a benign rupture or anastomotic
leak
Characteristic n=5 2
Age, year (mean ± SD) 60 (±14)
Gender, number of patients (%)
Male 32 (61)
Female 20 [39]
Cause of benign rupture or leak, number of patients (%)
Anastomotic 32 (62)
Iatrogenic 13 [25]
Boerhaave’s syndrome 4[ 8 ]
Other 3[ 5 ]
Location of benign rupture or leak, number of patients (%)
Distal esophagus 13 [25]
Mid-esophagus 24 (45)
Proximal esophagus 11 [21]
Unknown 4[ 9 ]
Length of rupture or leak, cm (median (range)) 2 (0.2-7)
Time interval between rupture and stent placement, number of patients (%)
Within 24 hours 5 [10]
After 24 hours 47 (90)
Prior treatment for benign rupture or leak, number of patients (%)
Stent placement in another hospital 3[ 5 ]
Surgery 3[ 5 ]
Clip placement 1[ 2 ]
None 45 (88)
Antibiotic treatment, number of patients (%)
Yes 41.(79)
No 11 [21]
Concurrent fluid drainage, number of patients (%)
Yes 24 (46)
No 28 (54)
Total days of treatment with a stent, median (range) 39 (1-742)
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cedure which successfully covered the leak.
In total, 71 (86%) stents were endoscopically removed
after a median of 25 (range 1-197) days (PSEMS 24 (1-
197) days, FSEMS 23 (1-120) days, SEPS 42 (14-90) days)
(p = 0.50). Of these, 52 were removed according to the
scheduled treatment plan, while the other 19 were
removed earlier due to the occurrence of complications
(Table 2). Endoscopic stent removal was successful in all
but eight patients with a PSEMS due to tissue in- and/or
overgrowth. In four of these patients, a FSEMS was
placed inside the PSEMS to achieve pressure necrosis,
after which the stent could be removed successfully
(stent-in-stent method) [24]. In one patient, the stent was
successfully removed during a follow-up endoscopic pro-
cedure 4 days later. In one patient esophagectomy was
performed for removal of the stent. In two patients, a
rupture occurred during stent removal, which necessi-
tated placement of another stent during the same proce-
dure to seal the rupture. These two stents could be
removed uneventfully, 17 and 23 days after placement.
Outcome and survival
Clinical success was achieved in 34 (76%, ITT: 65%)
patients (PSEMS: 73%, ITT: 69%; FSEMS: 83%, ITT: 56%;
SEPS: 83%, ITT: 71%, p = 0.33) after a median of 1 (range
1-5) stent and a median stenting time of 39 (range 7-120)
days (Figure 1, Table 2). Of the other 18 patients, 4
patients underwent surgical treatment (3 esophagectomy,
1 surgical repair), 2 patients had further conservative treat-
ment, 7 died before stent removal. One (2%) patient trea-
ted with FSEMS died from a stent-related death (severe
hemorrhage); this patient refused further interventions.
Another four patients died from rupture-related causes
Table 2 Outcome and survival of 52 patients treated with
83 esophageal stents for a benign perforation or
anastomotic leak
Characteristic
Technically successful stent placement, number of stents (%) 82/83 (99)
Technically successful stent removal, number of stents (%) 63/71 (89)
Reasons for stent removal, number of stents (%)
Scheduled 52 (73)
Early migration 9 [13]
Leakage through ruptured stent cover 6 [8]
Tissue in- and/or overgrowth 2 [3]
Severe pain 2 [3]
Clinical success, number of patients (%) 34 (65)
Cause of death, number of patients (%)
Rupture or leakage 4 [8]
Stent 1 [2]
Not related to rupture/leakage or stent placement 2 [4]
Figure 1 Endoscopic view: A Iatrogenic rupture following
pneumodilation, B Partially covered metal stent placed in the
esophageal lumen sealing the rupture, C Healed rupture after
stent removal.
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and one patient from active euthanasia.
Complications
In total, 33 complications in 24 patients (46%) occurred
(tissue in- and/or overgrowth (n = 8), stent migration (n =
10), ruptured stent cover (n = 6), food obstruction (n = 3),
severe retrosternal pain (n = 2), esophageal rupture due to
stent removal (n = 2) and hemorrhage (n = 2)) (Table 3).
Stent migration occurred most frequently with FSEMS
(20%), followed by SEPS (14%) and PSEMS (10%), while
tissue in- and/or overgrowth was only seen with PSEMS
(11%). Ruptured stent covers were only seen with Ultraflex
stents. In addition, severe pain and food obstruction were
also only seen in patients treated with PSEMS. In both
patients with unbearable pain, the stent was removed after
1 and 6 days. One patient underwent surgical treatment
(n = 1), while the other patient had conservative treatment
(n = 1). One hemorrhage occurred with a FSEMS and the
other with a PSEMS. One patient died (see above), while
the hemorrhage in the other patient was treated success-
fully with adrenaline injections. Two esophageal ruptures
occurred during removal of PSEMS. Ruptures occurred at
t h es i t eo ft h eu n c o v e r e ds tent meshes and these were
treated with a second stent (see above).
Discussion
To our knowledge, this is the first study comparing dif-
ferent stent types, i.e. FSEMS, PSEMS and SEPS, for
treatment of benign esophageal ruptures and leaks.
Furthermore, our patients were included in a relatively
short time compared to other cases series which makes a
non-randomized comparison between different stent
designs more reliable. Finally, all stents were placed in
centers with a high level of expertise in stent placement.
Clinical success was achieved in 34 (76%) patients with
no statistically significant differences between partially
and fully covered metal and plastic stents (PSEMS: 73%,
FSEMS: 83% and SEPS: 83%). This is in accordance with
previous studies reporting successful sealing rates of
48%-100% with no obvious differences between PSEMS
(48%-81%), FSEMS (48%-90%) and SEPS (67%-100%)
[14-18,25-37]. The median stenting time to achieve heal-
ing in our study was 39 days, which was also not different
from other studies, in which stenting time varied between
20 and 135 days [15,27,29,31,34,38]. Repeat endoscopy in
asymptomatic patients with a stent in situ for assessment
of healing was not routinely performed. Animal studies
have suggested that a stenting time of 30 days should be
enough for tissue healing [39]. Based on our results, we
recommend that removal of esophageal stents placed for
a rupture or leak should be performed after 5-6 weeks.
However, further studies are however needed to deter-
mine the ideal sealing conditions, which include stenting
time, type of stent to be used but also the extent of drai-
nage of extra-esophageal fluid. In the presence of fluid
collections in the pleural cavity or mediastinum, adequate
resolution of these fluid collections is an absolute prere-
quisite for complete healing of an esophageal rupture or
anastomotic leak. This can be done by endoscopic, radi-
ologic or surgical means [34,40].
The complication rate of stent placement in our series,
i.e., 33 complications in 24 patients (46%), was compar-
able to those reported in other series for this indication,
i.e. 20%-72%. Major complications that have been
reported include stent migration and tissue in- or over-
growth [14-17,27,28,33,36-38]. Stent migration occurred
in 10 of 52 patients in our series. Stent migration was
probably due to the fact that the far majority of these
patients had no obstructive lesion which could aid in
keeping the stent in place. Stent migration occurred most
frequently with fully covered stents. This is due to the
known reduced anchoring capacity of FSEMS and SEPS
compared to PSEMS [23,41]. Fixating FSEMS of SEPS to
the esophageal wall with an endoscopic clip has been
shown to be effective in preventing migration [42]. In our
study no attempts were made to endoscopically anchor
the stent.
In contrast, tissue in- or overgrowth was exclusively
seen with PSEMS (11%). Some endoscopists have a how-
ever a preference for PSEMS as it is thought that the nor-
m a le s o p h a g e a lt i s s u ea b o v ea n db e l o wt h er u p t u r eo r
leak can project through the uncovered stent mesh,
improving sealing quality and reducing the risk of stent
migration. It has been shown that this hyperplastic tissue
reaction results from a local fibrotic reaction and/or the
proliferation of granulation tissue. This can already be
seen as early as 14 days, but also at a later stage after
stent placement [43]. In our patients, tissue in- or over-
growth occurred between 33 and 211 (median 40) days
after stent placement. The type of stent material may
play a causative role in the formation of hyperplastic tis-
sue growth, with metal or nitinol stents being more
Table 3 Complications in 52 patients treated with an
esophageal stent for a benign rupture or anastomotic
leak
Complication Number (%)
Total complications 33 in 24 patients (46)
Stent migration 10
Tissue in- and/or overgrowth 8
Ruptured stent cover 6
Food obstruction 3
Hemorrhage 2
Severe pain 2
Ruptured esophagus (due to stent removal) 2
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from this, it is probably also associated with the radial
force and diameter of the stent, which may cause pres-
sure on the esophageal wall and in that way induce a
hyperplastic tissue reaction. Finally, duration of stenting
is also a factor, with a prolonged stenting time increasing
the risk. In our study, tissue in- and/or overgrowth com-
plicated removal of PSEMS in 8 patients. When PSEMS
are used for the treatment of benign ruptures or anasto-
motic leaks, we suggest to replace the stent on a 2-4
week basis. Alternatively, one may decide to leave the
PSEMS longer in place, in which case a fully covered
stent design of the same diameter can be placed inside
the stent (stent-in-stent method), as was described in the
Materials and Methods. This method allows uneventful
removal of both stents after 10-14 days [24].
Our mortality rate (10%) was in the same range as that
found in other studies (0-28%) [15-18,25-34,36-38]. Pre-
vious studies have reported that the time between onset
of rupture or leak and performing an intervention is the
most critical prognostic factor [2,10,12,18], with an
increasing delay between rupture or leak and treatment
being associated with a worse prognosis due to higher
occurrence of (septic) complications. In our study, all
patients that died had the stent placed more than 24
hours after the onset of rupture. Therefore, it seems clear
that treatment, i.e., sealing the rupture or leak, should be
performed as early as possible. The mortality rate (10%)
associated with stent placement for this indication is
likely to compare favorably with the mortality rate
reported for surgical management (12%-50%) [18].
Until now, it is unclear which rupture or leak should
be treated with stenting or primary surgery. Stenting has
been proposed for ruptures or leaks that are smaller
than 70% of the circumference [34], whereas surgery has
been proposed for larger ruptures or leaks. The only
true evidence would come from a randomized trial com-
paring these two treatment modalities, with special
reference to the underlying disorder, extent and time
since the rupture or leak occurred and severity of the
extra-esophageal contamination. Nevertheless, the lim-
ited number of patients for such a trial and the promis-
ing results of stenting make such a trial difficult if not
impossible to perform.
We are aware of the limitations of this study due to
the retrospective design of the study. First, there was a
variety of treatment protocols in our patients. In some
patients, stent removal or exchange was performed at
shorter intervals than in others and concurrent treat-
ment, such as drainage of fluid collections, was also dif-
ferent between patients. Consequently, this could have
affected clinical success rates, but also complication
rates. Furthermore, selection bias cannot be excluded in
our study, since there is still no guideline that clearly
defines which patient benefits from stenting and which
patient from surgery.
In conclusion, our results demonstrate that covered
stents, placed for a period of 5-6 weeks, are a treatment
option for sealing benign esophageal ruptures or leaks.
As efficacy between PSEMS, FSEMS and SEPS was not
different, stent choice should depend on expected risks
of stent migration (SEPS and FSEMS) and tissue in- or
overgrowth (PSEMS).
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